TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05438602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir
Description: Participants will receive 2 tablets of nirmatrelvir every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir
Description: Participants will receive 2 tablets of nirmatrelvir every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir
Description: Participants will receive 2 tablets of nirmatrelvir every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for nirmatrelvir
Description: Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for nirmatrelvir
Description: Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ritonavir
Description: Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ritonavir
Description: Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
Study: NCT05523596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICM20
Description: small molecules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICM20
Description: small molecules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICM20
Description: small molecules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICM20
Description: small molecules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: small molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: small molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: small molecule
Study: NCT06515132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCS Stimulation
Description: Participants will accept the SCS stimulus for six months

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation will be performed in the first three months after surgery, and SCS stimulation will be started in the fourth month after surgery
Study: NCT05260255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D2 ( calciferol )
Description: add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: add on placebo ( 2 cap ) for 12 weeks
Study: NCT05462990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUC398
Description: QUC398 150 mg/mL, solution for s.c. injection (1 mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0 mg/mL, solution for s.c. injection (1 mL)
Study: NCT05275010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)
Description: A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)
Description: A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handheld Syringe with Hypodermic Needle
Description: A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using a handheld manual syringe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-Body Delivery System
Description: A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using the on-body delivery system (OBDS).
Study: NCT05888844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description.
Study: NCT05853107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuTNA I
Description: AuTNA I means Au nanoparticle-decorated TiO2 Nanowire Arrays, a retinal prothesis designed for subretinal implantation.
Study: NCT06089460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef
Description: Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meat analogue
Description: Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beans/legumes
Description: Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
Study: NCT05858944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Home BP control
Description: If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Home BP control
Description: If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
Study: NCT05124327

Intervention type: OTHER
Group type: OTHER
Intervention: QI project- usage of RPM
Description: close monitoring through RPM to analyze feasibility and compare readmission rates
Study: NCT06537297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab
Description: * Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease.
Study: NCT05265494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive neuromodulation NESA (XSIGNAL device)
Description: The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~* 2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~* 4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~* 4 sessions: Program 7 (60min)
Study: NCT06053086

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Treatment ETHOS radiotherapy
Description: • Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IMRT
Description: • Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
Study: NCT05925283

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam and esketamine
Description: oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
Study: NCT02650271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Patients will be received entecavir (10 mg/d) before liver resection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Patients will be received tenofovir before liver resection.
Study: NCT06121141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full strength lidocaine with epinephrine
Description: 2% lidocaine with epinephrine 1:100,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilute lidocaine with epinephrine
Description: 2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
Study: NCT04803994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Locoregional therapy will be performed as a standard-of-care procedure
Study: NCT04743362

Intervention type: DIAGNOSTIC_TEST
Intervention: Dermoscopic imaging
Description: The skin lesion will be imaged before application of alcohol (spray/wipe) and after application of alcohol (spray/wipe). The dermatoscope/camera with dermoscopy imaging capabilities, including but not limited to VEOS® SLR (Canfield Scientific, Inc.), will be placed on/near the area(s) of interest. Images will be captured in polarized and/or nonpolarized modes and contact and/or non-contact modes.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3-dimensional total body photography
Description: Participants will stand in the center of an imaging station consisting of 92 high-resolution cameras. Image capture by all cameras will occur simultaneously, (approx. 3 milliseconds). Within a few minutes, specialized software will process and assemble the images into a 3D avatar - a digital model of the patient's skin - showing all his or her lesions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Confocal microscopy
Description: CM imaging (Vivascope®, Caliber Imaging and Diagnostics, Rochester, NY) will be performed using an arm-mounted CM device (Vivascope1500, Caliber I.D., Inc.) or using a handheld CM device (Vivascope3000, Caliber I.D., Inc.).

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography imaging
Description: OCT subsurface imaging shows structural-level morphology (epidermal and dermal layers) in skin down to the deeper reticular dermis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: US imaging allows assessment of depth, Doppler vascular imaging, and elastography features of skin lesions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperspectral imaging
Description: Hyperspectral imaging shows biochemical information regarding the distribution of skin melanin and hemoglobin50. SkinSpect™ is a form of a hyperspectral dermatoscope.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical impedance spectroscopy
Description: Electrical impedance spectroscopy (EIS) measures skin's resistance to the flow of alternating electric currents to differentiate benign and malignant lesions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient self-imaging
Description: Clinical and dermoscopy self-imaging by patients can be accomplished using mobile phone technology. In the case of dermoscopy, this requires a small dermatoscope attachment for the phone.
Study: NCT04672863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Modified Mediterranean diet approved by the Nutrition Team at the Transplant Center and it emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt (2-2.4g/day), moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats. The modifications to the traditional Mediterranean diet are: no alcohol consumption and fewer added fats. In addition, close scheduled followup on diet and progress with study team.
Study: NCT04601857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: futibatinib and pembrolizumab (KEYTRUDA®))
Description: Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: futibatinib and pembrolizumab (KEYTRUDA®))
Description: Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks
Study: NCT05501431

Intervention type: DEVICE
Intervention: Verily Study Watch
Description: The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.

Intervention type: DEVICE
Intervention: Verily Study Watch
Description: The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
Study: NCT05048342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).
Study: NCT06066697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOVA Ambassador
Description: The SOVA Ambassador intervention includes:~adolescents will have access to the website specifically for adolescents: sova.pitt.edu These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion.~Participants that receive this intervention will contribute monthly articles and regular comments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Reflection
Description: Participant will be given an article from the sova.pitt.edu website and a prompt to write about privately.
Study: NCT04303143

Intervention type: BEHAVIORAL
Intervention: Self-Hypnosis
Description: Self-Hypnosis

Intervention type: BEHAVIORAL
Intervention: Direct Autonomic Experience Control
Description: Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
Study: NCT06481280

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Test Formula
Description: Infants will receive an extensively hydrolyzed formula during the double-blind placebo-controlled food challenge (DBPCFC) and will continue on this formula during the open-label feeding phase if they tolerate it.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test Formula
Description: Infants will receive an extensively hydrolyzed formula during the double-blind placebo-controlled food challenge (DBPCFC) and will continue on this formula during the open-label feeding phase if they tolerate it.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formula
Description: Infants will receive a placebo formula during the DBPCFC to compare against the test formula.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Formula
Description: Infants will receive a placebo formula during the DBPCFC to compare against the test formula.
Study: NCT05607082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study: NCT04231058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS and pulmonary rehabilitation
Description: Three treatments with TENS per week for 3 weeks each , lasting 45 minutes
Study: NCT05719506

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: normal saline without drug
Description: nebulizer session with normal saline only preoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: nebulizer session with dexmedetomidine preoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: nebulizer session with ketamine preoperative
Study: NCT06320249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency rotation-traction manipulation
Description: The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-frequency rotation-traction manipulation
Description: The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical traction
Description: The procedure for cervical traction is as follows: The patient assumes a sitting position, and a cervical traction device with a chin strap is applied. The patient is instructed to slightly flex their head forward, approximately 10-15 degrees, based on their comfort level and symptom relief. Traction force starts at 3 kg and increases gradually in increments of 0.5 kg, with a maximum weight not exceeding 6 kg. The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
Study: NCT04606589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neoGuard vital signs monitor
Description: The neoGuardTM device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate, respiratory rate and blood oxygen saturation in newborns.
Study: NCT06334081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: undersized drilling technique
Description: In group A The implant site preparation was made according to the protocol of the manufacturer except that the final drill was omitted. The drilling was done using a low speed reduction, high torque with coolant contra-angle hand piece with surgical motor unit. Speed of drilling was 800-1200 rpm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single drilling technique
Description: In group B The implant bed was prepared using the new specially designed drills. First, the use of the guide drill of length 3.5mm with speed of 800 rpm and torque of 35 nm, then the use of the one drill of the same diameter of the selected implant size to the full length of the osteotomy site.